泛:在阿尔茨海默氏症疾病中潜在的治疗前景
1Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
The European journal of neuroscience
|August 18, 2025
概括
阿尔茨海默氏病 (AD) 可能涉及PANoptosis,这是一个细胞死亡过程,集成pyroptosis,apoptosis和necroptosis. 研究PANoptosis为AD提供了新的神经保护策略.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,具有重大的全球健康和社会经济影响.
- 目前针对阿尔茨海默氏症的粉样β (Aβ) 向疗法具有有限的疗效和显著的不良影响.
- 目前尚不完全了解阿尔茨海默病的确切原因和病理机制,需要新的治疗点.
研究的目的:
- 审查 PANoptosis 的分子驱动因素,这是一个被编程的细胞死亡途径.
- 评估PANoptosis在阿尔茨海默氏症病原发生中的潜在作用.
- 提出针对AD中PANoptosis的新型神经保护策略.
主要方法:
- 文献综述综合了关于PANoptosis的当前知识.
- 基于PANoptosis的分子机制的分析.
- 评估PANoptosis和AD病理学之间的潜在联系.
主要成果:
- 泛亡是一种协调的细胞死亡机制,涉及热亡,亡和亡.
- 虽然缺乏直接证据,但PANoptosis途径与各种疾病有关.
- 这篇评论提出了PANoptosis作为AD病变发生的潜在关键参与者.
结论:
- 泛亡代表了一种新的概念框架,用于理解细胞死亡.
- 向PANoptosis可能为阿尔茨海默病提供新的治疗途径.
- 需要进一步的研究来阐明PANoptosis在阿尔茨海默病中的直接作用,并开发有针对性的干预措施.
相关概念视频
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:15Parkinson's Disease: Overview
703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703
01:24Prosopagnosia
252
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
252